Anticoagulation for renally-impaired individuals with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) often entails balancing the risk of vascular events (e.g., stroke, pulmonary embolism) with the dangers of excess bleeding. In this CME Outfitters BriefCase series, two expert clinicians …
Patients and health care professionals (HCPs) face additional challenges when the treatments prescribed for pain management (e.g., opioids) lead to substance use problems. HCPs must then re-evaluate treatment plans for acute, subacute, and chronic pain and encourage treatment for opioid …
Recently, interleukin (IL)-23 and the inflammatory IL-23/T-helper (Th)-17 axis have been identified as central drivers of inflammation related to inflammatory bowel disease (IBD). Science in the field of cytokine-targeting therapies, specifically in the field of IL-23 P19 targeting agents, is …
Despite advances in the treatment and management of dermatologic conditions such as psoriasis, significant disparities in both treatment and outcomes persist for patients from racial/ethnic underserved groups. Patients of color are not only more likely to present with more severe …
Migraine is the most common neurological disorder, and the second most common cause of disability in the world. Despite the enormous cost it exacts on patients, the healthcare system, and the greater economy, migraine remains largely undertreated or un-treated. Racial …
Despite the rising prevalence of inflammatory bowel disease (IBD) among racial and ethnic underserved populations, disparities in diagnosis, treatment, and outcomes remain. Patients of color are more likely to present with more severe disease, sometimes with extraintestinal manifestations. However, even …
LGBTQIA+ patients struggle to engage with a health care system that is endlessly complex and almost completely unresponsive to their unique health needs. Medical students, student pharmacists, PA students, and nursing students receive very few LGBTQ+ curricular hours and report …
Recent advances in molecular classification of endometrial cancer (EC) have opened the door to better identification of adjuvant treatments that are more effective. Understanding how PD-L1 and PD-1 inhibitors contribute to improved efficacy in addition to standard of care in …